Alcohol-induced facial flushing in a patient with atopic dermatitis treated with dupilumab
Sean Igelman, Chanho Na, Eric L. Simpson
Abstract
Atopic dermatitis (AD) is a common, chronic type 2 inflammatory skin disease. Dupilumab (Dupixent; Regeneron, Tarrytown, NY), a fully humanized monoclonal antibody to the alpha subunit of interleukin 4 receptor, is the first and only targeted systemic treatment licensed to treat moderate to severe AD.1 Here, we report a case of a patient with repeated and clinically significant alcohol-induced facial flushing while taking dupilumab.
Topics & Concepts
DupilumabMedicineAtopic dermatitisDermatologyFlushingMonoclonal antibodyMonoclonalImmunologyAntibodyEndocrinologyDermatology and Skin DiseasesUrticaria and Related ConditionsFood Allergy and Anaphylaxis Research